UPDATE 1-King Pharma profit falls as Altace sales dive
(Rewrites first paragraph; adds details)
NEW YORK, May 8 (Reuters) - King Pharmaceuticals Inc (KG.N: Quote, Profile, Research) posted a 24 percent drop in first-quarter profit on Thursday as sales of its Altace blood-pressure drug plunged due to competition from generics.
Net income fell to $87.6 million, or 36 cents per share, from $115.9 million, or 48 cents per share, a year earlier.
Excluding one-time items, earnings were 37 cents per share, 2 cents ahead of analysts' average forecast, according to Reuters Estimates.
Revenue fell 16 percent to $432 million.
Sales of Altace, King's biggest-selling medicine until recently, dropped nearly 50 percent to $80 million. Altace began seeing U.S. competition from generic copies in December.
Sales of King's Skelaxin muscle relaxant nudged up 4 percent to $116 million. Sales of its Thrombin JMI product for controlling bleeding rose nearly 5 percent to $67 million.
Last October King said it would cut its work force by 20 percent, or 520 jobs, after its Altace patent was declared invalid. (Reporting by Lewis Krauskopf; Editing by Steve Orlofsky and John Wallace)
© Thomson Reuters 2009 All rights reserved
India Investment Summit 2009
Top executives and bankers discuss their own plans and the broader opportunities and challenges for India. Full Coverage
An icon bows to changing times
With his Playboy Enterprises in talks to be sold for about $300 million, the 83 year-old Hugh Hefner will be giving up control over the iconic adult entertainment empire he founded that was instrumental in shaping society's opinions on nudity, sex and free speech. Full Article





India
US
UK









